In 2013, the first clinical trial of immunotherapy showed that tremelimumab, a cytotoxic T‐lymphocyte protein 4 (CTLA‐4) inhibitor, improved objective response rates (ORRs) in HCC patients with HCV infection.17 This evidence concerns the gene CTLA4 and hepatocellular carcinoma.